BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 14754700)

  • 1. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
    Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
    Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus testing for primary screening of cervical cancer precursors.
    Ratnam S; Franco EL; Ferenczy A
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):945-51. PubMed ID: 11008913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
    Saraiya M; Irwin KL; Carlin L; Chen X; Jain N; Benard V; Montano DE
    Cancer; 2007 Sep; 110(5):1024-32. PubMed ID: 17628488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
    Wright TC
    Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
    Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
    Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic human papillomavirus testing in an adolescent population with atypical squamous cells of undetermined significance.
    Fletcher AH; Wilkinson EJ; Knapik JA
    J Low Genit Tract Dis; 2009 Jan; 13(1):28-32. PubMed ID: 19098603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods.
    Layfield LJ; Qureshi MN
    Diagn Cytopathol; 2005 Aug; 33(2):138-43. PubMed ID: 16007672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus detection: verification with cervical cytology.
    Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA
    Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
    Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of HPV testing in patients with possible high-grade cervical cytology.
    Rao A; Pather S; Dalrymple C; Mackie A; Deans R; Carter J
    J Obstet Gynaecol Res; 2009 Jun; 35(3):503-6. PubMed ID: 19527390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology.
    de Cremoux P; Coste J; Sastre-Garau X; Thioux M; Bouillac C; Labbé S; Cartier I; Ziol M; Dosda A; Le Galès C; Molinié V; Vacher-Lavenu MC; Cochand-Priollet B; Vielh P; Magdelénat H;
    Am J Clin Pathol; 2003 Oct; 120(4):492-9. PubMed ID: 14560561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodic health examination, 1995 update: 1. Screening for human papillomavirus infection in asymptomatic women. Canadian Task Force on the Periodic Health Examination.
    Johnson K
    CMAJ; 1995 Feb; 152(4):483-93. PubMed ID: 7859196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus in cervical screening and vaccination.
    Crosbie EJ; Kitchener HC
    Clin Sci (Lond); 2006 May; 110(5):543-52. PubMed ID: 16597323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of human papilloma virus testing in cervical cancer prevention.
    Fey MC; Beal MW
    J Midwifery Womens Health; 2004; 49(1):4-13. PubMed ID: 14710135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary human papillomavirus testing in organized cervical screening.
    Dillner J
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):11-6. PubMed ID: 23299089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus DNA after treatment of cervical dysplasia: low prevalence in normal cytologic smears.
    Bollen LJ; Tjong-A-Hung SP; van der Velden J; Mol BW; Lammes FB; ten Kate FW; ter Schegget J; Bleker OP
    Cancer; 1996 Jun; 77(12):2538-43. PubMed ID: 8640703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology.
    Bollen LJ; Tjong-A-Hung SP; van der Velden J; Mol BW; ten Kate FW; ter Schegget J; Bleker OP
    Gynecol Oncol; 1999 Feb; 72(2):199-201. PubMed ID: 10021301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collection devices for human papillomavirus.
    Harper DM; Hildesheim A; Cobb JL; Greenberg M; Vaught J; Lorincz AT
    J Fam Pract; 1999 Jul; 48(7):531-5. PubMed ID: 10428251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.